23.04.2015 Views

Purification of a Monoclonal Antibody Using the

Purification of a Monoclonal Antibody Using the

Purification of a Monoclonal Antibody Using the

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>Purification</strong> <strong>of</strong> a <strong>Monoclonal</strong> <strong>Antibody</strong> <strong>Using</strong> <strong>the</strong><br />

Ionela Iliescu 1 , Robert S. Gronke 1 ,<br />

1 <strong>Purification</strong> Development, Biogen Idec Inc, 14 Cambridge Center, Cambridge, MA 02142, USA<br />

Abstract<br />

The affinity ligand Protein A is a powerful tool to purify monoclonal antibodies. Though<br />

widely used by <strong>the</strong> Biotech industry, Protein A has several shortcomings including its high<br />

cost ($9,000 – $12,000/Liter), instability to strong base (i.e.1 N NaOH), leaching (ligand is<br />

toxic) and for some monoclonal antibodies, elution at low pH (< 3.5). ProMetic BioSciences,<br />

in collaboration with Biogen Idec Product Development have developed a small molecule<br />

affinity ligand called A2P that has been shown to be competitive to protein A. The affinity<br />

ligand was designed using combinatorial syn<strong>the</strong>sis, involvig controlled substitution to a<br />

triazine ring. Immunoglobulin binds to A2P in low salt through a hydrophobic interaction<br />

mechanism. The antibody binding capacity was found to be a function <strong>of</strong> ligand density and<br />

length <strong>of</strong> <strong>the</strong> spacer arm used. Pluronic F-68, a frequently used mammalian cell culture<br />

shear protectant, was found to interfere with antibody binding to <strong>the</strong> syn<strong>the</strong>tic affinity ligands.<br />

Thus, <strong>the</strong> cation exchanger Fractogel SO - 3 (EMD) was inserted as a first purification step to<br />

remove <strong>the</strong> Pluronic F-68.<br />

MAbsorbent ® A2P resin and a related syn<strong>the</strong>tic affinity resin, MAbsorbent ® A1P, also<br />

developed by ProMetic BioSciences were evaluated using a mammalian cell culture<br />

feedstream containing a monoclonal antibody (mAb1) produced at Biogen Idec. After<br />

capture on Fractogel SO - 3 <strong>the</strong> product was directly loaded onto MAbsorbent ® A1P or A2P<br />

adsorbents. The product was eluted <strong>of</strong>f <strong>the</strong> column using low pH. Both syn<strong>the</strong>tic affinity<br />

adsorbents performed similarly, resulting in good yields and >95% purity based on reduced<br />

gel chip analysis. An alternative elution condition using 60% ethylene glycol (EG) at neutral<br />

pH was also used for comparison. The majority <strong>of</strong> mAb1 was eluted <strong>of</strong>f A1P and A2P in <strong>the</strong><br />

60% EG fraction. The preliminary results suggest that <strong>the</strong> elution <strong>of</strong> <strong>the</strong> A2P resin with 60%<br />

EG may provide product with superior yield and purity.<br />

MAbsorbent Ligands<br />

Protein A Binding Site<br />

A1P<br />

Phe Tyr<br />

A2P<br />

Mimic<br />

Binding Capacity (mg IgG/mL Resin))<br />

25<br />

20<br />

15<br />

10<br />

5<br />

0<br />

Shorter Spacer Arms Improved IgG<br />

Binding Capacity <strong>of</strong> A2P<br />

0 2 3 4<br />

6 8 12<br />

Spacer Arm Length (# Carbons)<br />

Objectives<br />

• Develop an affinity column specific for humanized IgG expressed in mammalian cells<br />

as an alternative to protein A<br />

• Reduce process purification cost<br />

• Beta test <strong>the</strong> monoclonal antibody kit provided by ProMetic BioSciences with an<br />

industrial feedstream<br />

• Optimize kit procedure, if necessary, to improve purification results<br />

Methods<br />

• Reduced and non-reduced SDS-PAGE<br />

• Reduced and non-reduced gel chip<br />

• Size exclusion chromatography<br />

• Protein A HPLC assay for titer determination<br />

• TCID 50 assay for Mice minute virus (MMV) and Xenotropic Murine leukemia virus<br />

(X-MLV)<br />

Combinatorial Syn<strong>the</strong>sis Involves<br />

Controlled Substitution to a Triazine<br />

•Triazine structure is first coupled<br />

to resin<br />

•1st functional group is attached<br />

under mild conditions<br />

•2nd functional group is attached<br />

under more stringent conditions<br />

Agarose<br />

X<br />

N<br />

Cl<br />

N<br />

N<br />

Cl<br />

Triazine Structure<br />

Binding Capacity (mg IgG/mL Resin)<br />

40<br />

35<br />

30<br />

25<br />

20<br />

15<br />

10<br />

5<br />

0<br />

In General, Increasing Ligand Density<br />

Improved Binding Capacity <strong>of</strong> A2P<br />

2 Carbon 3 Carbon 6 Carbon<br />

0 5 10 15 20 25 30 35 40<br />

Ligand Density (µmoles epoxide/g)<br />

Evaluation <strong>of</strong> <strong>Antibody</strong> Capture Step<br />

Adsorbent Type Advantages Disadvantages<br />

Varied Affinity Column Components<br />

Variable length # / bead<br />

F-68 (cell culture media component)<br />

Reduced <strong>the</strong> Binding Capacity <strong>of</strong> IgG to<br />

<strong>the</strong> A2P Resin<br />

Protein A Very good yield and Biological product (protein ligand)<br />

high purity<br />

Difficult to clean/sanitize<br />

Good capacity<br />

Prone to degradation (leakage)<br />

Reasonable lifetime<br />

May harbor endotoxin<br />

Works for many mAb’s Expensive (>$9000/Liter)<br />

Syn<strong>the</strong>tic Affinity Easy to clean/sanitize Lack <strong>of</strong> commercially available choices<br />

Ligands Low cost ($1000-3000/Liter) Little regulatory experience<br />

High capacity (up to 50 mg/ml)<br />

Long lifetime<br />

Good purity<br />

Works for many mAb’s<br />

Agarose Spacer Arm<br />

Ligand<br />

IgG Binding Capacity (mg/mL)<br />

35<br />

Pure IgG<br />

30<br />

25<br />

Clarified Media<br />

20<br />

Pluronic F-68 (n = 140)<br />

15<br />

10<br />

5<br />

0<br />

0 0.5 1 1.5 2 2.5<br />

Concentration <strong>of</strong> F-68 (g/L)


ProMetic BioSciences <strong>Monoclonal</strong> <strong>Antibody</strong> Kit<br />

Jim Pearson 2 , and Keith Watson 2<br />

2 ProMetic BioSciences Ltd., 211 Cambridge Science Park, Milton Road, Cambridge CB4 0ZA, UK<br />

Replacement <strong>of</strong> Protein A with Mabsorbent ®<br />

Cell Culture Suspension<br />

Protein A Chromatography<br />

Harvest<br />

Clarified Supernatant<br />

Cation Exchange Chromatography<br />

MAbsorbent Chromatography<br />

Elution <strong>of</strong> A1P and A2P with Low pH<br />

•A1P and A2P Eluates have similar purity with low pH elution<br />

•However, <strong>the</strong> purity can be fur<strong>the</strong>r improved<br />

Columns were eluted with pH 3.5 (elution 1), 3.0 (elution 2) and 2.0 (strip).<br />

Eluates analyzed by reduced SDS-PAGE.<br />

A1P<br />

A2P<br />

Virus Clearance on A2P <strong>Using</strong> 60%<br />

Ethylene Glycol Elution (pH 7.8)<br />

Virus<br />

Removal<br />

(log 10)<br />

Inactivation<br />

(log 10)<br />

Total<br />

Clearance<br />

(log 10)<br />

MMV 4.9 < 1 4.9<br />

X-MLV > 3.7 2.0 > 5.7<br />

Fur<strong>the</strong>r purification/Formulation<br />

pH 3.5<br />

Elution<br />

pH 3.5<br />

Elution<br />

Kit Strategy for <strong>Purification</strong> <strong>of</strong><br />

<strong>Monoclonal</strong> Antibodies<br />

Clarified Culture Supernatant<br />

Adjust to pH 6<br />

Capture with Fractogel EMD SO 3<br />

-<br />

(cation exchange)<br />

Elute with 0.5 M NaCl<br />

<strong>Purification</strong> with MAbsorbent ® A1P/A2P<br />

Product/Analysis<br />

Elute with low pH<br />

Elution <strong>of</strong> A1P, A2P and rProtein A at pH 3.5<br />

% Total Half <strong>Antibody</strong> by NR Gel Chip<br />

20<br />

17.5<br />

A “half antibody”<br />

15<br />

variant was cleared<br />

10.7<br />

more efficiently by<br />

9.8 9.5<br />

A<br />

B<br />

<strong>the</strong> syn<strong>the</strong>tic affinity<br />

10<br />

ligands compared to<br />

rProtein A resin.<br />

5<br />

0<br />

IEX A1P Eluate A2P Eluate rPA Eluate<br />

% Aggregate by SEC<br />

25<br />

20.4<br />

Aggregate level with<br />

20 C<br />

D<br />

A2P or A1P was<br />

15<br />

much lower than that<br />

9.4<br />

<strong>of</strong> rProtein A eluate<br />

10<br />

4.1 4.0<br />

5<br />

0<br />

IEX A 1P Eluate A2P Eluate rPA Eluate<br />

Conclusions<br />

• Development <strong>of</strong> syn<strong>the</strong>tic affinity resin<br />

Optimized spacer arm length and ligand density increased <strong>the</strong> binding<br />

capacity <strong>of</strong> A2P with pure IgG<br />

Fractogel EMD SO 3- used as <strong>the</strong> capture step if feedstream contains<br />

pluronic F-68<br />

• Evaluation <strong>of</strong> syn<strong>the</strong>tic affinity resins (A1P and A2P) for purification<br />

<strong>of</strong> mAb1<br />

Lower pH <strong>of</strong> clarified cell culture supernatant required for efficient<br />

capture <strong>of</strong> mAb1 on Fractogel EMD SO -<br />

3<br />

Evaluation <strong>of</strong> alternative elution conditions: low pH or 60% ethylene<br />

glycol at neutral pH<br />

Preliminary results indicate that elution <strong>of</strong> A2P with 60% ethylene<br />

glycol at neutral pH may provide superior yield and purity<br />

60% EG elution step gave good clearance <strong>of</strong> MMV and X-MLV<br />

• Cost analysis: two-step non-Protein A purification was<br />

approximately 50% <strong>the</strong> cost <strong>of</strong> Protein A process<br />

Results – <strong>Purification</strong> <strong>of</strong> mAb1<br />

•Poor capture <strong>of</strong> mAb1 on Fractogel SO 3- at pH 6.0<br />

•Capture <strong>of</strong> mAb1 improved at pH 4.7<br />

Fractogel – Load at pH 4.7<br />

Alternative Elution: 60% Ethylene Glycol<br />

Elution, pH 7.8<br />

Higher product yield and purity with A2P than with A1P<br />

Columns were eluted with 60% EG (pH 7.8) followed by elution with pH 3.5 (elution 1),<br />

3.0 (elution 2), and 2.0 (strip). Fractions analyzed by reduced SDS-PAGE.<br />

A1P<br />

Loss <strong>of</strong><br />

Product<br />

A2P<br />

Removal <strong>of</strong><br />

impurities<br />

Acknowledgments<br />

Biogen Idec Inc.<br />

Prometic BioSciences Ltd.<br />

Douglas Cecchini, Ph.D. Dev Baines, Ph.D.<br />

Jörg Thömmes, Ph.D.<br />

Michael Duell<br />

Anisa Vaidya<br />

Peter Bonnett<br />

Christine Poliks<br />

Steve Burton<br />

Light<br />

Chain Loss<br />

Light<br />

Chain Loss<br />

Primedica<br />

Kate Bergmann<br />

60% EG Eluate 60% EG Eluate

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!